As discussed in part one of this two part series, both Verastem and AVEO appear to be going to the ASCO conference this weekend with minimal updates pertaining to their pipeline. With volatility and depressed stock price of each company, this was rather disappointing. In part one, I covered Verastem's presentation at ASCO, and here in part two, I will go over what it appears AVEO will be bringing to ASCO . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.